The Biomimetic MicroEngineering (BioME) Laboratory advances bioinspired engineering principles to elucidate fundamental mechanisms underlying human health and disease. Central to our work is the human Organ-on-a-Chip, also known as the Microphysiological System (MPS), a next-generation experimental platform that accurately recapitulates host-microbiome ecosystems and predicts human physiological responses with fidelity unattainable by conventional models. We have engineered novel biomimetic architectures that reconstitute the three-dimensional physical microstructure, organ-level physiological functions, and dynamic biomechanical forces of the living human gut.
A defining focus of the laboratory is the emulation of host-microbiome interactions that govern intestinal homeostasis and drive disease pathogenesis. Working in close collaboration with clinical partners, we have developed a breakthrough "Personalized Disease-on-a-Chip" framework that integrates patient-derived organoids, patient-specific microbiomes, and primary immune cells into a single, controllable platform. This technology has enabled mechanistic investigation of microbiome-mediated pathology across a spectrum of gastrointestinal diseases, including inflammatory bowel disease (IBD), encompassing Crohn's disease and ulcerative colitis, colorectal cancer, and enteric infectious diseases.
Our overarching scientific mission is to distinguish causality from consequence in host-microbiome crosstalk across diverse disease contexts, leveraging patient-specific Disease-on-a-Chip models as precision research tools. Looking forward, we are expanding our biomimetic platform to model pathophysiological processes across multiple organ systems, including the oral cavity, nasal airway, vaginal tract, placenta, skin, liver, and gut-brain axis. Ultimately, we are committed to translating this disruptive technology into tangible impact for the scientific, clinical, and pharmaceutical communities, accelerating the resolution of high-priority, high-risk medical challenges.
The Biomimetic MicroEngineering (BioME) Laboratory advances bioinspired engineering principles to elucidate fundamental mechanisms underlying human health and disease. Central to our work is the human Organ-on-a-Chip, also known as the Microphysiological System (MPS), a next-generation experimental platform that accurately recapitulates host-microbiome ecosystems and predicts human physiological responses with fidelity unattainable by conventional models. We have engineered novel biomimetic architectures that reconstitute the three-dimensional physical microstructure, organ-level physiological functions, and dynamic biomechanical forces of the living human gut.
A defining focus of the laboratory is the emulation of host-microbiome interactions that govern intestinal homeostasis and drive disease pathogenesis. Working in close collaboration with clinical partners, we have developed a breakthrough "Personalized Disease-on-a-Chip" framework that integrates patient-derived organoids, patient-specific microbiomes, and primary immune cells into a single, controllable platform. This technology has enabled mechanistic investigation of microbiome-mediated pathology across a spectrum of gastrointestinal diseases, including inflammatory bowel disease (IBD), encompassing Crohn's disease and ulcerative colitis, colorectal cancer, and enteric infectious diseases.
Our overarching scientific mission is to distinguish causality from consequence in host-microbiome crosstalk across diverse disease contexts, leveraging patient-specific Disease-on-a-Chip models as precision research tools. Looking forward, we are expanding our biomimetic platform to model pathophysiological processes across multiple organ systems, including the oral cavity, nasal airway, vaginal tract, placenta, skin, liver, and gut-brain axis. Ultimately, we are committed to translating this disruptive technology into tangible impact for the scientific, clinical, and pharmaceutical communities, accelerating the resolution of high-priority, high-risk medical challenges.
The Biomimetic MicroEngineering (BioME) Laboratory advances bioinspired engineering principles to elucidate fundamental mechanisms underlying human health and disease. Central to our work is the human Organ-on-a-Chip, also known as the Microphysiological System (MPS), a next-generation experimental platform that accurately recapitulates host-microbiome ecosystems and predicts human physiological responses with fidelity unattainable by conventional models. We have engineered novel biomimetic architectures that reconstitute the three-dimensional physical microstructure, organ-level physiological functions, and dynamic biomechanical forces of the living human gut.
A defining focus of the laboratory is the emulation of host-microbiome interactions that govern intestinal homeostasis and drive disease pathogenesis. Working in close collaboration with clinical partners, we have developed a breakthrough "Personalized Disease-on-a-Chip" framework that integrates patient-derived organoids, patient-specific microbiomes, and primary immune cells into a single, controllable platform. This technology has enabled mechanistic investigation of microbiome-mediated pathology across a spectrum of gastrointestinal diseases, including inflammatory bowel disease (IBD), encompassing Crohn's disease and ulcerative colitis, colorectal cancer, and enteric infectious diseases.
Our overarching scientific mission is to distinguish causality from consequence in host-microbiome crosstalk across diverse disease contexts, leveraging patient-specific Disease-on-a-Chip models as precision research tools. Looking forward, we are expanding our biomimetic platform to model pathophysiological processes across multiple organ systems, including the oral cavity, nasal airway, vaginal tract, placenta, skin, liver, and gut-brain axis. Ultimately, we are committed to translating this disruptive technology into tangible impact for the scientific, clinical, and pharmaceutical communities, accelerating the resolution of high-priority, high-risk medical challenges.
The Biomimetic MicroEngineering (BioME) Laboratory advances bioinspired engineering principles to elucidate fundamental mechanisms underlying human health and disease. Central to our work is the human Organ-on-a-Chip, also known as the Microphysiological System (MPS), a next-generation experimental platform that accurately recapitulates host-microbiome ecosystems and predicts human physiological responses with fidelity unattainable by conventional models. We have engineered novel biomimetic architectures that reconstitute the three-dimensional physical microstructure, organ-level physiological functions, and dynamic biomechanical forces of the living human gut.
A defining focus of the laboratory is the emulation of host-microbiome interactions that govern intestinal homeostasis and drive disease pathogenesis. Working in close collaboration with clinical partners, we have developed a breakthrough "Personalized Disease-on-a-Chip" framework that integrates patient-derived organoids, patient-specific microbiomes, and primary immune cells into a single, controllable platform. This technology has enabled mechanistic investigation of microbiome-mediated pathology across a spectrum of gastrointestinal diseases, including inflammatory bowel disease (IBD), encompassing Crohn's disease and ulcerative colitis, colorectal cancer, and enteric infectious diseases.
Our overarching scientific mission is to distinguish causality from consequence in host-microbiome crosstalk across diverse disease contexts, leveraging patient-specific Disease-on-a-Chip models as precision research tools. Looking forward, we are expanding our biomimetic platform to model pathophysiological processes across multiple organ systems, including the oral cavity, nasal airway, vaginal tract, placenta, skin, liver, and gut-brain axis. Ultimately, we are committed to translating this disruptive technology into tangible impact for the scientific, clinical, and pharmaceutical communities, accelerating the resolution of high-priority, high-risk medical challenges.
Hyun Jung Kim, Ph.D. is an Associate Staff in the Department of Inflammation and Immunity at the Cleveland Clinic and Principal Investigator of the Biomimetic MicroEngineering (BioME) Laboratory. Where the laboratory builds the platforms, Dr. Kim's research program drives the scientific vision underlying them, advancing bioinspired engineering principles to create next-generation biomedical technologies that bridge mechanistic discovery with clinically actionable innovation.
Dr. Kim is internationally recognized for pioneering miniaturized human Organ-on-a-Chip MPS that faithfully recapitulate the structural architecture, functional physiology, and mechanical dynamics of the human intestine. His laboratory has established foundational biomimetic methodologies for modeling host-microbiome interactions under physiologically relevant flow and mechanical forces, with landmark publications in Advanced Science (2026), PNAS (2016, 2018), Nature Protocols (2022), and Nature Reviews Bioengineering (2024), collectively advancing patient-specific disease modeling and precision interrogation of complex host-microbiome ecosystems. By converging clinical microbiology, microfluidics, and tissue engineering, Dr. Kim's group has uncovered critical mechanistic insights into inflammatory, fibrotic, and oncologic pathologies driven by host-microbiome crosstalk, positioning organ-on-a-chip technology as a rigorous alternative to conventional in vitro and animal models.
His contributions have been recognized by competitive awards, including the NIH NCI IMAT Award (2025, 2018), Kenneth Rainin Foundation Innovator Awards (2024, 2016), VeloSano 10 Pilot Award (2024), Crohn's & Colitis Foundation Senior Research Award (2023), and the Cancer Research Institute Technology Impact Award (2018).
ACADEMIC & PROFESSIONAL APPOINTMENT
07/2022 – present Cleveland Clinic, Cleveland Clinic Research, Cleveland, OH, USA
10/2026 – present Associate Staff, Department of Inflammation and Immunity
10/2026 – present Associate Staff, Department of Biomedical Engineering (Joint Appointment)
07/2022 – 10/2026 Assistant Staff, Department of Inflammation and Immunity
02/2023 – 10/2026 Assistant Staff, Department of Biomedical Engineering (Joint Appointment)
04/2023 – present Assistant Professor, Department of Biomedical Engineering, Cleveland Clinic Lerner College of Medicine (CCLCM) of Case Western Reserve University
01/2015 – 06/2022 The University of Texas at Austin, Austin, TX, USA
Assistant Professor, Department of Biomedical Engineering, Cockrell School of Engineering
EDUCATION & TRAINING
Harvard University, Boston, MA, USA
09/2012 – 12/2014 Technology Development Fellow, Wyss Institute for Biologically Inspired Engineering (Advisor: Donald E. Ingber, MD, PhD)
07/2009 – 08/2012 Postdoctoral Fellow, Wyss Institute for Biologically Inspired Engineering (Advisor: Donald E. Ingber, MD, PhD)
The University of Chicago, Chicago, IL, USA
03/2007 – 06/2009 Postdoctoral Scholar, Department of Chemistry (Advisor: Rustem F. Ismagilov, PhD)
Yonsei University, Seoul, Republic of Korea
09/2005 – 02/2007 Research Associate, Institute of Life Science and Biotechnology (Advisor: Chul Soo Shin, PhD)
09/2000 – 08/2005 PhD in Biotechnology (Advisor: Chul Soo Shin, PhD)
03/1998 – 08/2000 MS in Biotechnology (Advisor: Chul Soo Shin, PhD)
03/1994 – 02/1998 BE in Biotechnology
AWARDS & HONORS (Selected)
2025 Appreciation Award, Cleveland Clinic Foundation, USA (Apr and Jun)
2025 Catalyst SPARK Awards, Cleveland Clinic Foundation, USA
2024-2026 Innovator Awards, Kenneth Rainin Foundation, USA
2024 VeloSano 10 Pilot Award, VeloSano and Cleveland Clinic, USA
2024-2026 Ewha Global Fellow (EGF), Ewha Womans University, Seoul, Korea
2023-2026 Senior Research Award, Crohn’s and Colitis Foundation of America, USA
2023 2022 Inventor, Office of Innovations, Cleveland Clinic Foundation, USA
2023 CTSC Core Utilization Pilot Grant Award, Case Western Reserve University, USA
2022 Career Development Program Award, Lerner Research Institute, Cleveland Clinic, USA
2021 2020 Research Excellence in Korean Biomedical Science, Medical Research Information Center, Korea
2018 Technology Impact Award, Cancer Research Institute (CRI), USA
2017 Texas 4000 Seed Grant Award, Dept. of Biomedical Engineering, UT Austin, USA
2016 Innovator Awards, Kenneth Rainin Foundation, USA
2015 Featured Designer for Organs-on-Chips, Museum of Modern Art (MoMA), New York, USA
2013 Abcam Discovery 15 Contest Finalist ($1,000 credit), USA
2013 2013 Invented Here! Honoree. New England’s Breakthrough Inventions and Inventors. Boston, MA, USA
2013 Best Paper Award. ALine, Inc., 2013 ASME (NEMB 2013). Feb 4-6, 2013, Boston, MA, USA
2012 - 2014 Wyss Technology Development Fellowship, Wyss Institute, Harvard University, USA
2012 Best Presentation Award for Postdocs. The Korean Toxicologists Association in America. SOT 2012, San Francisco, CA, USA
2012 Postdoctoral Award (1st place). In Vitro and Alternative Methods Special Section, SOT 2012, San Francisco, CA, USA
2007 - 2008 Leo Kadanoff and Stuart Rice Postdoctoral Fellowship, The University of Chicago, USA
2003 - 2004 Fellowship for Young Scientist, Korea Research Foundation, Korea
2001 Scholarship for Excellent Student, Yonsei University, Seoul, Korea
"CIMER Trained Mentor" indicates the principal investigator has completed mentorship training based on curriculum from the Center for the Improvement of Mentored Experiences in Research, aimed at advancing mentoring relationships and promoting cultural change in research.
The Biomimetic MicroEngineering (BioME) Laboratory advances bioinspired engineering principles to elucidate fundamental mechanisms underlying human health and disease. Central to our work is the human Organ-on-a-Chip, also known as the Microphysiological System (MPS), a next-generation experimental platform that accurately recapitulates host-microbiome ecosystems and predicts human physiological responses with fidelity unattainable by conventional models. We have engineered novel biomimetic architectures that reconstitute the three-dimensional physical microstructure, organ-level physiological functions, and dynamic biomechanical forces of the living human gut.
A defining focus of the laboratory is the emulation of host-microbiome interactions that govern intestinal homeostasis and drive disease pathogenesis. Working in close collaboration with clinical partners, we have developed a breakthrough "Personalized Disease-on-a-Chip" framework that integrates patient-derived organoids, patient-specific microbiomes, and primary immune cells into a single, controllable platform. This technology has enabled mechanistic investigation of microbiome-mediated pathology across a spectrum of gastrointestinal diseases, including inflammatory bowel disease (IBD), including Crohn's disease and ulcerative colitis, colorectal cancer, and enteric infectious diseases.
Our overarching scientific mission is to distinguish causality from consequence in host-microbiome crosstalk across diverse disease contexts, leveraging patient-specific Disease-on-a-Chip models as precision research tools. Looking forward, we are expanding our biomimetic platform to model pathophysiological processes across multiple organ systems, including the oral cavity, nasal airway, vaginal tract, placenta, skin, liver, and gut-brain axis. Ultimately, we are committed to translating this disruptive technology into tangible impact for the scientific, clinical, and pharmaceutical communities, accelerating the resolution of high-priority, high-risk medical challenges.
View publications for Hyun Jung Kim, PhD
(Disclaimer: This search is powered by PubMed, a service of the U.S. National Library of Medicine. PubMed is a third-party website with no affiliation with Cleveland Clinic.)
Selected Publications
November 15, 2026
Biomimetic Microengineering (BioME) Lab (PI: Hyun Jung Kim, PhD) at the Cleveland Clinic has developed a human Organ-on-a-Chip that recapitulates a complex host-microbiome ecosystem to model various human diseases. By integrating patient-derived cells, microbes, and biomechanical cues, we create a personalized Disease-on-a-Chip to uncover disease mechanisms and identify novel therapeutic strategies. We are seeking highly motivated researchers to join our interdisciplinary team and work on the following projects advancing innovation in translational science, engineering, and medicine.
POSITION 1: Advanced Engineering for Multiscale Organ-on-a-Chip Platforms
We are hiring highly motivated candidates to advance our multiscale Organ-on-a-Chip platform, built for scalable experimentation through configurable modules and a cost-effective, reproducible design. Ideal candidates will have expertise in one or more of the following: i) mechanical engineering, mechatronics, or automation/robotics, including precision mechatronic design for multiscale laboratory systems with embedded automation; ii) 3D printing, rapid prototyping, and precision manufacturing for multiscale cell culture platform development; or iii) microfluidics, microfabrication, or microengineering to integrate microscale biological models with automated system control. All ranks will be considered, including postdoctoral, Master’s-level, and research technician candidates.
POSITION 2: Microbiome-Associated Disease Modeling in Organ-on-a-Chip Platforms
We are seeking talented postdoctoral candidates to join collaborative projects investigating how the gut microbiome orchestrates human gastrointestinal (GI) diseases, including inflammatory bowel disease (IBD) such as Crohn’s disease (CD) and ulcerative colitis (UC), intestinal fibrosis, colorectal cancer (CRC), and infectious diseases. Our transdisciplinary initiatives, in collaboration with physician-scientists, immuno-oncologists, and pharmaceutical partners, aim to elucidate microbiome-driven mechanisms of disease development, advancing precision therapeutics and translational medicine.
POSITION 3: Pharmacomicrobiomics in Human Organ-on-a-Chip Platforms
We are seeking a postdoctoral candidate to advance Organ-on-a-Chip platforms for studying host-microbiome interactions in drug pharmacology. The candidate will apply systems pharmacology approaches to elucidate mechanisms of drug metabolism, absorption, and toxicity for orally administered compounds, while developing and optimizing high-throughput, cost-effective platforms that accelerate pharmaceutical discovery and reduce reliance on animal models. This role offers the opportunity to help define next-generation approaches to precision pharmacology and translational therapeutics.
Skills Required: Candidates must have rigorous scientific training in research design and analysis. A strong track record of previous research achievements is highly valued. Ideal candidates should demonstrate expertise in at least one of the following areas: i) human microphysiological system (MPS) or NAMs, ii) mechanical engineering, device design and manufacturing, system automation, or mechatronics engineering, iii) adult stem cell or iPSC-based tissue engineering and organoids, iv) GI mucosal biology, cancer biology, or cancer immunology, or v) clinical microbiology and host-microbiome interactions.
Applicants are required to send i) a CV and ii) a cover letter to [email protected]. In the cover letter, please highlight the qualifications pertinent to the project outlined in the job description and include a list of 3 references.
Our education and training programs offer hands-on experience at one of the nationʼs top hospitals. Travel, publish in high impact journals and collaborate with investigators to solve real-world biomedical research questions.
Learn MoreIn inflammatory bowel disease, colon cells lining the intestine are more susceptible to physical damage and scarring.